A Phase 2 Randomized Open-Label Study of Oral ODM-201 vs. Androgen Deprivation Therapy (ADT) With LHRH Agonists or Antagonist in Men With Hormone Naive Prostate Cancer
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2016
At a glance
- Drugs Darolutamide (Primary) ; Degarelix; Goserelin; Leuprorelin; Triptorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 28 Nov 2016 Planned End Date changed from 1 Jun 2021 to 1 Jul 2021.
- 28 Nov 2016 Planned primary completion date changed from 1 Feb 2020 to 1 Mar 2020.